Gilead signs licensing deals for HIV treatment

Gilead Sciences has signed licensing agreements with the Medicines Patent Pool (MPP) and generic companies to provide greater access to HIV treatment bictegravir.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Insilico lands potential $2.5bn AI biotech partnership

22 June 2026 The partnership, announced at BIO 2026, marks the largest Asia-Pacific partnership by potential value that the AI-driven drug discovery company has secured to date.

Biotechnology

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

4 June 2026 The deal gives Pfizer access to 12 early-stage oncology programmes and marks the latest in a growing wave of high-value licensing agreements between Big Pharma and Chinese biotechs.

Biotechnology

Gilead to pay up to $5bn for antibody-drug conjugates push

8 April 2026 The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.

More features

Insilico lands potential $2.5bn AI biotech partnership

‘Blatant imitation’: Indian court blocks copycat pharma branding

UPC hands Occlutech second win against Chinese medtech company in a month

US life sciences damages averaged $33.5m between 2019-2025

Quantum and photonics tech licensing expert joins EIP

Court upholds $83m sequencing verdict and sets royalty rate

Exclusive: ‘Cultural differences are an asset’ at the UPC

Amgen and subsidiary dealt $20m blow over rodent antibody tech

Gilead signs licensing deals for HIV treatment

More on this story

Editor's picks

Editor's picks

More features